Chantix users should be monitored for suicidal behavior, depressed mood, says FDA

The Food and Drug Administration on Friday said of Pfizer's smoking-cessation drug Chantix that "it appears increasingly likely that there may be an association between Chantix and serious neuropsychiatric symptoms," the Wall Street Journal reports.

In its public health advisory, the FDA said Chantix users should be monitored for suicidal behavior, depressed mood and other changes in behavior.

Sales of the drug totaled $280 million for the fourth quarter of 2007. The drug was approved by the FDA in May, 2006.

For information on smoking-cessation group seminars in your area, contact Dr. David Ross, ND.

Medicine | Health | Alternative Health News | Stop Smoking | Smoking Cessation Program | Nutritional Supplements | HerbBlurbs.com | AltHealthNews.com